At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...

Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

DelveInsight's Metastatic Non-Small Cell Lung Cancer Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, February 5, 2025 ...

The presentation was sent to our distribution list by email, and you can also find it on gsk.com. Please turn to ... continuing life cycle innovation for Jemperli. In HIV, our plans for long ...

Specialty medicines accounted for more than 80% of GSK's growth in 2024, led by oncology and respiratory immunology. Benlysta grew 14%, while Jemperli sales tripled, benefiting from expanded FDA ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by new patient starts across all regions. New blood cancer drug Ojjaara/Omjjara generated ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a ...

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an ...